Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Randomized, Single-Blinded Study to Evaluate the Safety and Immunogenicity of 80 µg Recombinant Plague Vaccine (rF1V) With and Without Adjuvant at Two Vaccination Schedules in Healthy Adult Volunteers

NCT01122784 is registered in ClinicalTrials.gov with DynPort Vaccine Company LLC, A GDIT Company as lead sponsor.

NCT NCT01122784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01122784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Randomized, Single-Blinded Study to Evaluate the Safety and Immunogenicity of 80 µg Recombinant Plague Vaccine (rF1V) With and Without Adjuvant at Two Vaccination Schedules in Healthy Adult Volunteers
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2010
Completion date
July 31, 2012
Enrollment
402 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

plague vaccine